Inhibition of Cdk Activity
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Cancer-Critical Genes II: Tumor Suppressor Genes
M-Cdk Drives Transition Into Mitosis
Combination Therapies and Personalized Medicine
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Mar 6, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Daniel C Beachler1, Vincent Lo Re2, Stephan Lanes1
1Carelon Research, Wilmington, Delaware.
No abstract available in PubMed .
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012